51794-07-1

Upstream product

• 614-75-5 2-Hydroxyphenylacetic acid 
• 939-82-2 1-bromo-2-(bromomethyl)-4-nitrobenzene 
• 52761-10-1 2-(2-bromo-5-nitrophenyl)acetonitrile 
• 7149-70-4 2-bromo-5-nitrotoluene 
• 123-76-2 levulinic acid 
• 52427-03-9 2-(2-bromo-5-nitrophenyl)acetic acid 

Downstream Products

• 116435-83-7 (2-hydroxy-5-nitro-phenyl)-acetic acid ethyl ester 
• 21997-23-9 5-nitro-3H-benzofuran-2-one 
• 155388-58-2 2-hydroxy-5-nitrophenylacetic acid methyl ester 
• 155388-60-6 N-Benzyloxy-2-(2-hydroxy-5-nitro-phenyl)-acetamide 
• 155388-59-3 2-hydroxy-5-nitro-N-tert-butoxyphenylacetyl amide 
• 155388-84-4 (2-hydroxy-5-aminophenyl)acetic acid 
• 155388-71-9 benzyl 2-hydroxy-5-nitrobenzoate 
• 138563-98-1 methyl 2-methoxy-5-nitrophenylacetate 
• 155388-88-8 2-hydroxy-5-amino-N-(benzyloxy)phenylacetyl amide 
• 154737-65-2 5-Amino-2-hydroxy-benzoic acid benzyl ester 
• 155388-86-6 (5-Amino-2-hydroxy-phenyl)-acetic acid ethyl ester 

Relevant academic research and scientific papers

Preparation method of 2,5-diamino phenethyl alcohol

The invention discloses a preparation method of 2,5-diamino phenethyl alcohol. The method comprises the following steps that prepared 5-nitro-2-amino-benzene acetic acid is dissolved into diethyl ether, FeCl3 and MnO2 are added, nitrogen is introduced, th

NPY ANTAGONISTS, PREPARATION AND USES

The present invention concerns novel compounds, their preparation and their uses, therapeutic uses in particular. More specifically it concerns derivative compounds having at least two aromatic cycles, their preparation and their uses, in particular in the area of human or animal health. These compounds have an affinity for the biological receptors of neuropeptide Y, NPY, present in the central and peripheral nervous systems. The compounds of the invention are preferably NPY antagonists, and more particularly antagonists of sub-type NPY Y1, and can therefore be used for the therapeutic or prophylactic treatment of any disorder involving NPY. The present invention also concerns pharmaceutical compositions containing said compounds, their preparation and their uses, as well as treatment methods using said compounds.

Investigation of novel 7,8-disubstituted-5,10-dihydro-dibenzo[b,e][1,4]diazepin-11-ones as potent Chk1 inhibitors

The synthesis and structure-activity relationships (SAR) of Chk1 inhibitors based on a 5,10-dihydro-dibenzo[b,e][1,4]diazepin-11-one core are described. Specifically, an exploration of the 7 and 8 positions on this previously disclosed core afforded compounds with improved enzymatic and cellular potency.

Compositions and methods for enhancing drug delivery across biological membranes and tissues

This invention provides compositions and methods for enhancing delivery of drugs and other agents across a biological barrier, including epithelial tissues such as the skin, gastrointestinal tract, pulmonary epithelium, and the like. The compositions and

Leaving group effects in reductively triggered fragmentation of 4-nitrobenzyl carbamatesf

The rates and extent of release of a series of substituted anilines from 4-nitrobenzyl carbamates, following nitro group reduction by radiolytic, enzymic and chemical methods, are reported. The yield of released anilines decreased over the pH range 4-7, b

Structure-activity relationships in a series of 5-[(2,5- dihydroxybenzyl)amino]salicylate inhibitors of EGF-receptor-associated tyrosine kinase: Importance of additional hydrophobic aromatic interactions

Potent inhibitors of EGF-dependent protein tyrosine kinase (PTK) activity were synthesized in a series of 5-[(2,5-dihydroxybenzyl)amino]salicylates. Several of these compounds inhibited EGF-dependent DNA synthesis in ER 22 cells with IC50 1 μ